Anti-PD-1 Antibody Formulation Stability Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Anti-PD-1 antibodies used in pharmaceutical formulations are prone to chemical instability, including oxidation, when stored over long periods and under varying environmental conditions, which affects their stability and shelf life.
Innovation Solution
A pharmaceutical formulation comprising an anti-PD-1 antibody with specific concentrations of citrate, histidine, mannitol, sodium chloride, edetate, and polysorbate, along with a pH range of 5.5 to 6.5, which includes two light chains and two heavy chains with specific amino acid sequences, is developed to maintain stability and prevent degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If anti-PD-1 antibodies are stored over long periods and under varying environmental conditions, then the antibody concentration can be maintained, but chemical instability including oxidation occurs
Solution Approach 1:
The patent optimizes multiple formulation parameters simultaneously: pH (5.5-6.5), buffer concentrations (citrate 15-25 mM, histidine 20-30 mM), excipient concentrations (mannitol 130-165 mM, NaCl 45-55 mM), and antioxidant concentrations (edetate 0.01-0.03 mM, polysorbate 0.01-0.03%). This multi-parameter optimization resolves the contradiction by creating a formulation environment that simultaneously maintains stability and extends shelf life
Solution Approach 2:
The patent introduces edetate (EDTA) and polysorbate as intermediary substances that act as antioxidants and stabilizers. These intermediaries protect the anti-PD-1 antibody from oxidation and chemical degradation by scavenging free radicals and preventing direct contact between the antibody and oxidizing agents in the environment
2Ease of operation
If the formulation is designed for stability at room temperature, then ease of storage is improved, but stability under temperature fluctuations and light exposure deteriorates
Solution Approach 1:
The patent creates a universal formulation system that provides stability across multiple environmental conditions (room temperature, refrigerated temperatures, temperature fluctuations, and light exposure). The combination of buffers, excipients, and antioxidants works synergistically to protect the antibody regardless of specific environmental variations, making the formulation universally stable across different storage and transport conditions
3Productivity
If higher concentration of anti-PD-1 antibody is used in formulation, then dosage efficiency is improved, but physical and chemical stability deteriorates
Solution Approach 1:
The patent optimizes the antibody concentration parameter to 10 mg/mL, which balances dosage efficiency with stability. This concentration is supported by optimized buffer capacities (citrate and histidine concentrations) and excipient levels (mannitol and NaCl) that maintain physical and chemical stability at this therapeutic concentration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively maintains the physical and chemical stability of the anti-PD-1 antibody, preventing oxidation and degradation, even under extreme conditions, thereby extending its shelf life and ensuring stability for extended periods.
Implementation Method 1
Anti-PD-1 antibodies used in pharmaceutical formulations are prone to chemical instability, including oxidation, when stored over long periods and under varying environmental conditions
Implementation Method 2
A pharmaceutical formulation comprising an anti-PD-1 antibody with specific concentrations of citrate, histidine, mannitol, sodium chloride, edetate, and polysorbate, along with a pH range of 5.5 to 6.5
Implementation Method 3
mannitol at a concentration of about 130 mM to about 165 mM, sodium chloride at a concentration of about 45 mM to about 55 mM
Data Source
AI summary
Provided herein are pharmaceutical formulations for anti-PD-1 antibodies.